NAGENCMHealthcare·Biotechnology#263 in industry

Niagen Bioscience, Inc.

Reports in 10d· 2026-05-06

-21.0% · 90d

$4.93

+0.00 (+0.00%)

News

No News Yet

Press releases and SEC filings for NAGE will appear here as they are published.

Check back later for updates

Key Data

Market Cap$394.8M

Open$4.95

Prev Close$4.93

Day Range$4.92 – $5.06

52W Range$4.16 – $14.69

Volume481,554

P/E (TTM)24.65

EPS$0.20

Dividend Yield—

Beta2.23

Profit Margin13.43%

Revenue Growth16.20%

Price Target$13.60(+175.9%)

Next Earnings2026-05-06(10d)

Analyst Ratings

Strong Buy5 analysts

Buy 5Hold 0Sell 0

About

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Healthcare · Biotechnology

117 employees

www.niagenbioscience.com